Pain
Ralf Baron. Research over the past decade has unravelled a variety of independently operating pain mechanisms, but our patients have not yet seen the fruits of this endeavour, and approval of new pain medi cations is rare. One reason for this state of affairs is the obvious heterogeneity of pain mechanisms. Thus, the potential of novel compounds addressing specific therapeutic targets is often obscured if a heterogeneous group of patients is included in trials that evaluate the average pain reduction for the entire cohort. The next decade will see dramatic changes in trial design, and in the clinical management of patients with pain.
When designing clinical trials, identi fication of the responding patient is an important factor. A complex cornucopia of clinical characteristics, including psycho social factors, comorbidities, sensory abnormalities, and pathophysiological mechanisms, are likely to influence the over all response to pain treatment, 1, 2 and the specific clinical response pattern depends on the drug or intervention used. 3 Statistical modelling of treatment response, using data from existing and new trials, should reveal certain clinical baseline profiles that will increase the likelihood of response. Knowledge about predictive pathophysio logical mechanisms will, consequently, be translated back into basic research.
Relevant outcome parameters must also be determined. A commonly used end point in trials and in the clinic is the change in pain intensity averaged over the past 3 days. In reality, however, patients experience a complex temporal pattern of painful sensa tions. Some individuals perceive only a few severely painful attacks per day, in others the pain depends on movement, and often there are painfree periods during the night. How can a patient calculate an average of these sensations over 3 days? Alternative outcome parameters that capture the individual pain related quality of life and functionality need to be developed to account for the complex perception of pain and its consequences as precisely as possible.
For shared decisionmaking between patients and physicians, and in light of shrinking health resources, careful evaluation of the risks and benefits of pain management is a prerequisite. The above approaches will help us to success fully implement the individualization of pain therapy.
Child neurology Donna M. Ferriero. We are witnessing an illuminating period in child neurology, and discoveries abound that will inform practice and research for the next decade. The past 10 years saw the advent of therapeutic hypo thermia for neonatal encephalopathy, and the results have been sufficiently encoura ging to make this approach the standard of care in this scenario. 4 However, the protec tion afforded by therapeutic hypothermia is not complete, so the search for adju vant therapies continues. The addition of erythro poietin to therapeutic hypothermia has shown promising results in early clini cal trials, especially for perinatal stroke. 5 The use of stem cells represents another potential avenue to treat neonatal encepha lopathy, and is being tested in pilot studies. 6 Cellbased therapies have also been used to correct inborn errors of metabolism, such as lysosomal storage diseases. 7 Precision medicine will pave the way for more appropriate and targeted therapies in the next decade. De novo and rare inherited copy number variations (CNVs) are recog nized to underlie the clinical manifestations of a growing list of neurodevelopmental conditions. For example, genomewide analysis in cerebral palsy-not traditionally thought to be genetically determined-has uncovered a large number of chromosomal abnormalities associated with the disease. 8 These findings were substantiated in a recent study, which determined the impact of de novo CNVs on the diagnosis and classification of cerebral palsy. 9 Similarly promising results have been obtained in other neurological condi tions, including epileptic encephalo pathies. The Epilepsy Phenome/Genome Project used exomebased sequence data to highlight novel candidate genes related to infantile spasms and Lennox-Gastaut syndrome. 10 Our understanding of the clinically heterogeneous neuromuscular disorders, such as the congenital muscu lar dystrophies, has also benefited from unbiased genomic approaches. The contributors* A combined CNV and singlenucleotide variant data approach is expediting the dis covery of new syndromes and genes involved in neuropsychiatric diseases associ ated with developmental delay, despite considerable genetic heterogeneity. 12 Perhaps the disease that has benefited most from novel techno logies is autism: both de novo missense muta tions and de novo likely genedisrupting (LGD) mutations contribute to diagnosis. 13 The next decade will be about levera ging the knowledge buried in genomics to define the causes of and treatments for p aediatric neurological diseases.
Alzheimer disease
Giovanni B. Frisoni. If you wish to know where you are going, first ask your self where you are coming from. A decade ago, patients with cognitive complaints typi cally consulted me after 3.5 years of cogni tive symptoms, and diagnosis of Alzheimer disease (AD) was largely based on structural imaging (CT or MRI) to rule out second ary causes. Biomarkers such as cortical hypometabolism on 18 FFDG-PET, hippo campal atrophy on MRI, and cerebrospinal fluid (CSF) biomarkers (amyloidβ 42 and tau) were reserved for the few with early symptoms or an unclear clinical picture. The typical patient diagnosed with AD had a mean MiniMental State Examination (MMSE) score of 20/30, treatment was based on symptomatic drugs only, and dis appointment was still raging about the dra matic failure of AN1792, the first candidate AD modifier. 14 My typical patient of 2015 has a history of cognitive complaints of 12 months or less. In my academic memory clinics, we use imaging and CSF biomarkers for most patients. In the context of reallife diagnostic research studies, we include quantitated and automated imaging biomarker readouts in the clinical reports ( 18 FFDG-PET metrics of cortical hypometabolism, automated hippo campal volume extraction algorithms), 15 and we have access to molecular imaging biomarkers that allow in vivo neuropatho logical analysis (for example, amyloid PET). 16 Patients diagnosed with AD typically have an MMSE score of 25-26/30 and little or no disability, and most are given symptomatic drugs and are usually enrolled in clinical trials of secondgeneration antiamyloid or antitau disease modifiers, some of which are providing early indications of effectiveness. 17, 18 In 2025, I expect that early diagnosis of AD with molecular (imaging and CSF) biomarkers will be daily practice in all memory clinics worldwide, and patients will be prescribed a cocktail of drugs aimed at both improving symptoms and delay ing disease progression. The main efforts, however, will be directed towards asymp tomatic people with the molecular signature of AD (brain amyloidosis or tau). 19 These individuals will be screened in the popula tion with blood and genetic biomarkers, [20] [21] [22] and will be treated with disease modifiers to prevent the onset of cognitive symptoms and disability. This wellknown disease prevention paradigm is analogous to the treatment of hyper tension and hyperchol esterolaemia to prevent cardiovascular and cerebrovascular events.
The toughest challenge will be to promote brain health by changing lifestyles in the population. An impressive amount of evi dence indicates that physical activity has multiple benefits for vascular, cognitive and emotional health; 23, 24 however, people are reluctant to take up running, swim ming or cycling for the sake of health alone. Scientists should stop advocating the need for yet another clinical trial on the cogni tive benefits of healhy lifestyles, 23 and lobby decisionmakers to implement societal poli cies to actively promote these lifestyles. This approach will substantially benefit not only the brain, but society overall.
Neuro-oncology
Chetan Bettegowda and Ziya L. Gokaslan.
The past decade has seen an explosion in the understanding of the molecular and genetic basis of dozens of tumour types, ignited by advances in our ability to study systems at a global level, and at an unprecedented pace. For many tumour types, our improved knowledge of the tumour-host interaction, the critical pathways that lead to tumori genesis, and the mechanisms that under lie treatment response and resistance have led to the development of new therapies, including those that modulate the immune system or target specific genetic alterations. These discoveries have led to dramatic improvements in outcomes for a number of cancer types. Unfortunately, although the scientific advances in neurooncology have kept pace with those in other areas of oncology, the translation of this knowledge has been slow to improve patient outcomes.
Median survival for glioblastoma, the most common brain cancer, remains meas ured in months, with nearly all patients even tually succumbing to the disease. There is a dearth of FDAapproved therapies for nearly all CNS malignancies. One factor in our inability to adequately treat these tumours is the failure of historical classification methods to appreciate their complexity. Within any broad category of cancers affecting the CNS, genetic, epigenetic and proteomic profil ing has revealed the existence of multiple subtypes. 25 These molecular characteristics can be predictive and prognostic, and have already begun to guide treatment selec tion in certain patient populations, such as SMO inhibitors in SHHdriven medullo blastoma, and tyrosine kinase inhibition in BRAFmutant gliomas. 26, 27 In the next 10 years, we anticipate that the pathological diagnosis of CNS tumours will incorporate routine comprehensive molecu lar characterization. The knowledge derived from such detailed investigations of tumour specimens will enable significant advances, providing the basis for novel therapeutic and diagnostic strategies. CNS malignancies fall into the category of rare diseases, with each affecting only a few thousand individuals around the world, making appropriate clini cal trials difficult to conduct. Grouping of patients into wellcurated populations that are comparable at the subcellular level will allow the execution of clinical trials in popu lations that are most likely to benefit. These advances will, hopefully, lead to the improve ments in survival that we are all so desperate to witness.
Regenerative neurology
John A. Kessler. The field of neurologi cal therapeutics has blossomed over the past decade, with therapies that can both prevent disease progression and treat symp toms, but at present no techniques are avail able for regenerating the damaged nervous system. The next decade will witness the advent of regenerative neurol ogy, a broad term that encompasses regeneration, replacement and/or engineering of cells to restore normal nervous system function. This change will reflect the convergence of advances in stem cell biology, gene therapy, materials science and nanotechnology, and geneediting techniques (for example, the TALENS and CRISPR-Cas9 geneediting platforms). 28, 29 [32] [33] [34] Although these early trials might dem onstrate some clinical benefits, their effi cacy will be limited by both technical and bio logi cal constraints, and strategies that combine new technologies are likely to be required. For example, stem cells require a highly regulated microenvironment, or 'niche', to survive, differentiate and integrate-an issue that is not addressed by current trials. Biomaterials can be designed to promote transplant survival and integra tion, both by providing the neces sary cell-matrix inter actions and through localized delivery of drugs or proteins. 35, 36 Convergent technologies will be required to explore the potential of RNA interfer ence or short hairpin RNAs to knock down levels of mutant proteins in inherited neuro logical diseases 37 or, even more remarkably, to correct the defective gene sequences via geneediting techniques. 28, 29 This effort will require new vectors-both viral and nonviral-that are being developed to overcome the problems that have impeded gene therapy to date. 32, 33 The advent of such combinatorial approaches in the next decade will help to launch a new era of regenerative neurology.
Epilepsy
Annamaria Vezzani. Epilepsy is a devasta ting neurological disease that afflicts approx imately 1% of the world's population. Over the past 10 years, working as a basic scientist in the field of experimental epilepsy, I have witnessed the emergence of important new knowledge related to the basic mechanisms of the generation and recurrence of epi leptic seizures-the main hallmark of epilepsy. Studies in animal models and in vitro brain cell and slice preparations have been instru mental in deepening our understanding of the molecules and pathways involved in the pathogenesis of seizures, and in the adaptive changes that the brain undergoes to reestablish homeostasis and promote repair. 38, 39 These mechanisms represent an invaluable source of potential targets for drug and biomarker discovery.
Unfortunately, the development of new therapies lags behind the advances in basic research. In around 40% of people with epi lepsy, the seizures cannot be controlled by the available antiepileptic drugs (AEDs). Even in responsive patients, the AEDs mainly provide symptomatic control of seizures, and often produce serious adverse effects. 40, 41 Nextgeneration therapies need to have diseasemodifying properties to halt or reverse the progression of epilepsy, or to prevent its onset in susceptible individu als. This unmet clinical need represents a translational research priority for the next decade. In addition, an intensive search is underway for EEG, imaging and circulating biomarkers of epilepsy onset and prognosis, and for prediction of the therapeutic effects of drugs. 42, 43 The availability of biomarkers will be instrumental in the development of a new generation of therapies that are better targeted to the brain pathological processes in people who have epilepsy or are at high risk of developing the disease.
In the coming years, substantial efforts will be devoted to addressing the patho genic mechanisms underlying comorbidi ties such as cognitive deficits, depression and autism spectrum disorders, which severely affect quality of life in people with epilepsy, especially those in the paediatric population. 44 In the context of preclinical research, it will be critical to refine animal models of adult and paediatric epilepsies to improve biomarker validation and drug discovery. 45 In addition, novel approaches are being developed, including the use of simple model organisms such as zebrafish (Danio rerio) to model acute seizures and genetic epilepsies, 46 and the generation of patientspecific neurons through induced pluri potent stem cell reprogramming to facilitate the development of cellbased novel drugs. 47 Finally, technological improvements in diagnostic and research tools are ongoing. These include moresophisticated EEG recording modalities for monitoring and predicting seizures in patients, optogenetic based approaches for halting seizures, new devices for delivering drugs on demand, and improved and novel noninvasive molecu lar brain imaging approaches. 40, [48] [49] [50] [51] This armamentarium, together with increas ingly sensitive and informative 'omics' and genetic approaches, 52,53 will help us not only to increase our knowledge of this multi faceted and complex disease, but also to markedly improve the therapeutic options for patients.
Channelopathies
Stephen G. Waxman. The prototypical antiepileptic medication phenytoin was dis covered nearly a century ago. When pheny toin was introduced into clinical practice, its mode of action was not understood, but we now know that it acts, in large part, by blocking sodium channels. Since the advent of phenytoin, a stream of additional compounds that target ion channels have been developed.
Over the past decade, the pace of prog ress has quickened. A remarkable conver gence of genetics, ion channel biology and neurology has yielded dramatic and far reaching advances in our understanding of ion channels and their roles in human disease. Ion channels are increasingly being implicated in epileptiform disorders, and sodium channels have been shown to have important pathogenetic roles in disorders including myotonias and periodic paralyses, migraine, and peripheral neuro pathy. [54] [55] [56] [57] [58] Studies on channelopathies-disorders caused by mutations in genes encoding spe cific ion channels-have firmly established a role for sodium channels such as Na V 1.7 (encoded by SCN9A) as central players in human pain. 59 In concert, therapeu tic molecules that block specific subtypes of sodium channels while sparing others are under development. 60 Advanced tech niques for atomiclevel molecular model ling, 61 together with the solution of the crystal structure of prototypical bacterial sodium channels, have propelled molecular pharmacology to new levels.
The next decade promises to be even more exciting. In my opinion, we are likely to see rapid translation of these advances into the therapeutic realm. I predict that within the next 10 years, new, more effective therapies for pain that target 'peripheral' molecules such as the sodium channels Na V 1.7, Na V 1.8 and Na V 1.9 will enter the clinical domain. Given that the target molecules are crucial for electro genesis in peripheral painsignalling
''
The toughest challenge will be to promote brain health by changing lifestyles... '' '' Precision medicine will pave the way for more appropriate and targeted therapies in the next decade '' neurons but have little, if any, role in the brain, these new pain medications should not affect the brain and, thus, will not have central adverse effects such as sedation, confusion, ataxia or diplopia, and will not have addictive potential. I also anticipate that new genomically guided approaches to chronic pain, in which medications are matched to the genomic makeup of the patient, will transform pain management from 'trial and error' to 'first time around' .
Finally, I believe that additional channel opathies of the nervous system are likely to soon be discovered soon. Evidence is emerging that Na V 1.8 sodium channels, which are not normally present within the cerebellum, are expressed by Purkinje neurons in patients with MS. 62 This anom alous expression leads to mistuning of these critically important cere bellar output neurons, which in turn leads to clinical dys function. Experiments in animal models have already demonstrated that some of the symptoms produced by this channelopathy can be ameliorated by blocking the offend ing molecules. 63 Hopefully, these findings will provide a basis for development of new targeted therapies for MS.
Autoantibody-related disorders
Sven Jarius and Brigitte Wildemann. Over the past 10 years, we have witnessed the dis covery of numerous autoantibodyrelated neurological disorders, and the field is still growing. Of particular importance was the identification of aquaporin4 (AQP4), the most abundant water channel in the CNS, as an antibody target in patients with neuro myelitis optica and its formes frustes, 64 and the discovery of Nmethyldaspartate receptors (NMDARs) and the voltage gated potassium channel (VGKC) complex proteins LGI1 and CASPR2 as antigens in limbic encephalitis. 65 Testing for AQP4IgG is of the utmost importance in the differential diagno sis of MS, particularly if optic neuritis, myelitis (mostly longitudinally extensive) and/or brainstem encephalitis are present, as some treatments that have been shown to be bene ficial in MS-for example, IFNβ, natalizumab and fingolimod-are consid ered to be ineffective or even detri mental in AQP4 encephalomyelitis. The availabil ity of NMDARIgG and VGKCcomplex IgG testing has made it possible to identify patients with encephalitis who are likely to respond to immunotherapy.
In AQP4 and NMDAR encephalo myelitis, a direct pathogenic role of the respective antibodies is highly likely, and the therapeutic and prognostic implica tions have been formally demonstrated. 66, 67 By contrast, the pathogenic impact of other antibodies with high differential diagnostic potential still needs to be studied in more detail. Further antineuronal reactivities identified over the past 10 years include, among others, antibodies to AMPAR, GABA B R, GABA A R, glycine receptors, mGluR5 and DPPX in encephalitis; ITPR1, Homer3, CARP, PKCγ, and ARHGAP26 in cerebellitis (termed 'Medusa head ataxia' [68] [69] [70] ); LRP4 in myasthenia gravis; and CASPR2 in neuro myotonia. Moreover, a new role in antiAQP4negative myelitis and optic neur itis, as well as in acute dis seminated encephalomyelitis, has been assigned to antimyelin oligodendrocyte glycoprotein antibodies. 71 These findings have substantially facili tated the laboratory diagnosis of neuro logical autoimmune disorders. However, the rapid increase in numbers of poten tially useful antibody markers also pres ents considerable diagnostic challenges. Currently, a multitude of commercial and inhouse assays are used, some of which might be insufficiently sensitive and/or specific. 72 Given the potentially dramatic therapeutic consequences of false test results, future research should focus not only on identifying new antibody markers, but also on developing highly standard ized immuno assays. In this context, emphasis needs to be placed on imple mentation of regular (international) inter laboratory comparison trials for the most important novel autoanti bodies, as well on creating the necessary institutional structures to perform such trials in a manufacturerindependent fashion.
A particular threat lies in the discrep ancy between the low prevalence of many of the newly described autoantibodies and the high number of tests requested in daily practice by physicians who wish to offer their patients the most extensive diagnos tic workup available. However, testing for rare markers in large, unselected popula tions always carries the risk of an unfavour able ratio of falsepositive to truepositive results, even if highly specific test methods are used. Therefore, the development of consensus guidelines on antibody testing in neurology, which inform physicians who are not experts in neuroimmunol ogy about indications for antibody testing, seems warranted.
General neurology
Michael Weller. Over the past decade, neurology has evolved dramatically from a mainly diagnostic-and often consid ered largely academic-speciality into a broadbased clinical discipline with multi ple ramifications and subspecializations, increasingly focused on innovative and tar geted therapeutic interventions. The next decade will undoubtedly see even greater changes and challenges for a clinical dis cipline that combines highly specialized, complex interventions with patient care at the community level, across a wide range of countries with highly variable healthcare systems and resources.
Some core areas of neurology have seenand should continue to see-major thera peutic advances. Examples include deep brain stimulation and other interventional treatments in PD, 73 highly effective (but also potentially dangerous) immune inter ventions in MS, 74 and the reemergence of early multidisciplinary intervention, as well as an evolving area of neurorehab ilitation, in stroke. 75, 76 Other areas with a bright future include those where neurol ogy is working closely with neighbour ing disciplines, hopefully more often in a cooperative than a competing fashion. In dementia, for example, neurologists are collaborating with psychiatrists and geri atric specialists to determine how to dis tribute the workload of clinical research, intervention and care, 77 and how to prepare our ageing societies for this major socio economic challenge. Neurooncology is a prototypical multidisciplinary discipline, in which we anticipate major advances in technical (in particular, neurosurgical) and immunological interventions. 78 Future challenges for the neurology field include a balanced focus on research, education and patient care, and the inevi table redefinition of the main duties of neurologists. We need to evaluate the importance of clinical examination skills, and technical expertise in neurology associated techniques, such as ultrasound, EEG and electro neuro myography. In addition, we must weigh up the costs and benefits of the increasing repertoire of diagnostic resources.
''
Future challenges for the neurology field include a balanced focus on research, education and patient care… '' PERSPECTIVES
